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Continuous processing offers significant advantages for the processing of unstable recombinant products such 
as therapeutic plasma proteins. As such we have established a development platform to assess potential 
purification steps as part of a continuous linear process using a standard AKTA Explorer. Following a consistent 
format of IEX membrane to HIC membrane to affinity resin, we were able to rapidly investigate multiple 
purification pathways for a recombinant blood protein. Using membranes as the first two steps enables a 3-step 
purification process to be carried out in 3 to 4 hours, with a total turnaround of 5 to 6 hours including 
regeneration and re-equilibration, at laboratory scale and depending on the specific pathway. This development 
method allowed for a direct comparison between multiple purification pathways, assessing overall recovery, 
pathway consistency, product quality and product purity over the 3 steps. Ligands tested include cation & anion 
exchangers, phenyl, phenyl boronate and an immobilised affinity peptide. It is envisaged that once a purification 
pathway has been decided upon, processing speed could be around 1 L per day without significant scale-up. 
 
